Tango Therapeutics vs Xilio Therapeutics
TNGX and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TNGX and XLO compare
Tango Therapeutics is the larger company, worth 92 times as much as Xilio Therapeutics ($4.3B against $46.7M).
Xilio Therapeutics grew revenue faster over the last twelve months (73.0% versus −100% for Tango Therapeutics).
Xilio Therapeutics scores higher on the StockData Score (11 against 8 for Tango Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TNGX | XLO |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $46.7M |
| Share price | $25.50 | $8.07 |
| Change, 1 year | 232% | −25.4% |
| Change, 5 years | 113% | −97.5% |
| Beta (5Y) | 1.18 | 0.89 |
| Employees | 137 | 76 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.8× |
| P/B | 4.4× | 0.7× (better) |
| FCF yield | −3.5% (better) | −123% |
| Fair value | – | $31.67 |
| Margin of safety | – | 74.5% |
| Growth | ||
| Revenue growth (TTM) | −100% | 73.0% (better) |
| Revenue growth, 5Y average | 52.1% | – |
| Profitability | ||
| Operating margin | – | −74.9% |
| Net margin | – | −20.9% |
| FCF margin | – | −105% |
| Return on equity | −36.5% (better) | −38.2% |
| Return on invested capital | −3646% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 39.45 (better) | 4.72 |
| Altman Z-score | 47.76 (better) | −3.87 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 127% | 58.9% |
| Held by insiders | 11.7% | – |
| Insider net buying, 12 months | −$8.0M | $38.3K (better) |
| Short interest, % of float | 32.4% | – |
Go deeper
- TNGX stock overview
- TNGX income statement
- TNGX valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.